ID   DCK_HUMAN               Reviewed;         260 AA.
AC   P27707; B2R8V6; Q5TZY7; Q6FI11;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1992, sequence version 1.
DT   12-APR-2017, entry version 160.
DE   RecName: Full=Deoxycytidine kinase;
DE            Short=dCK;
DE            EC=2.7.1.74;
GN   Name=DCK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 58-70; 119-127 AND
RP   189-192.
RX   PubMed=1996353; DOI=10.1073/pnas.88.4.1531;
RA   Chottiner E.G., Shewach D.S., Datta N.S., Ashcraft E., Gribbin D.,
RA   Ginsburg D., Fox I.H., Mitchell B.S.;
RT   "Cloning and expression of human deoxycytidine kinase cDNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:1531-1535(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PARTIAL PROTEIN SEQUENCE, AND CHARACTERIZATION.
RX   PubMed=2013338; DOI=10.1016/0014-5793(91)80332-W;
RA   Eriksson S., Cederlund E., Bergman T., Joernvall H., Bohman C.;
RT   "Characterization of human deoxycytidine kinase. Correlation with cDNA
RT   sequences.";
RL   FEBS Lett. 280:363-366(1991).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9342341; DOI=10.1073/pnas.94.22.11941;
RA   Johansson M., Brismar S., Karlsson A.;
RT   "Human deoxycytidine kinase is located in the cell nucleus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:11941-11945(1997).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-74, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   PHOSPHORYLATION AT SER-11; SER-15; THR-72 AND SER-74 BY CSNK1D/CK1.
RX   PubMed=20637175; DOI=10.1016/j.abb.2010.07.009;
RA   Smal C., Vertommen D., Amsailale R., Arts A., Degand H., Morsomme P.,
RA   Rider M.H., Neste E.V., Bontemps F.;
RT   "Casein kinase 1delta activates human recombinant deoxycytidine kinase
RT   by Ser-74 phosphorylation, but is not involved in the in vivo
RT   regulation of its activity.";
RL   Arch. Biochem. Biophys. 502:44-52(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-74, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-74, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) IN COMPLEX WITH ADP;
RP   DEOXYCYTIDINE; ARAC AND GEMCITABINE, CATALYTIC ACTIVITY, SUBUNIT,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ALA-100; ARG-104 AND
RP   ASP-133.
RX   PubMed=12808445; DOI=10.1038/nsb942;
RA   Sabini E., Ort S., Monnerjahn C., Konrad M., Lavie A.;
RT   "Structure of human dCK suggests strategies to improve anticancer and
RT   antiviral therapy.";
RL   Nat. Struct. Biol. 10:513-519(2003).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) IN COMPLEX WITH ADP AND
RP   CLOFARABINE, AND SUBUNIT.
RX   PubMed=16421443; DOI=10.1107/S0907444905034293;
RA   Zhang Y., Secrist J.A. III, Ealick S.E.;
RT   "The structure of human deoxycytidine kinase in complex with
RT   clofarabine reveals key interactions for prodrug activation.";
RL   Acta Crystallogr. D 62:133-139(2006).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEXES WITH ADP;
RP   D-DEOXYCYTIDINE; L-DEOXYCYTIDINE AND EMTRICITABINE.
RX   PubMed=17530837; DOI=10.1021/jm0700215;
RA   Sabini E., Hazra S., Konrad M., Lavie A.;
RT   "Nonenantioselectivity property of human deoxycytidine kinase
RT   explained by structures of the enzyme in complex with L- and D-
RT   nucleosides.";
RL   J. Med. Chem. 50:3004-3014(2007).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.77 ANGSTROMS) IN COMPLEXES WITH
RP   D-DEOXYADENOSINE; L-DEOXYADENOSINE; ADP AND UDP, CATALYTIC ACTIVITY,
RP   AND FUNCTION.
RX   PubMed=18377927; DOI=10.1016/j.jmb.2008.02.061;
RA   Sabini E., Hazra S., Ort S., Konrad M., Lavie A.;
RT   "Structural basis for substrate promiscuity of dCK.";
RL   J. Mol. Biol. 378:607-621(2008).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.31 ANGSTROMS), CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF ARG-104 AND ASP-133.
RX   PubMed=19159229; DOI=10.1021/bi802062w;
RA   Hazra S., Sabini E., Ort S., Konrad M., Lavie A.;
RT   "Extending thymidine kinase activity to the catalytic repertoire of
RT   human deoxycytidine kinase.";
RL   Biochemistry 48:1256-1263(2009).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 20-260 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=19836232; DOI=10.1016/j.bmcl.2009.09.081;
RA   Jessop T.C., Tarver J.E., Carlsen M., Xu A., Healy J.P.,
RA   Heim-Riether A., Fu Q., Taylor J.A., Augeri D.J., Shen M.,
RA   Stouch T.R., Swanson R.V., Tari L.W., Hunter M., Hoffman I.,
RA   Keyes P.E., Yu X.C., Miranda M., Liu Q., Swaffield J.C.,
RA   David Kimball S., Nouraldeen A., Wilson A.G., Foushee A.M., Jhaver K.,
RA   Finch R., Anderson S., Oravecz T., Carson K.G.;
RT   "Lead optimization and structure-based design of potent and
RT   bioavailable deoxycytidine kinase inhibitors.";
RL   Bioorg. Med. Chem. Lett. 19:6784-6787(2009).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.96 ANGSTROMS) IN COMPLEX WITH ADP AND
RP   5-METHYL-DEOXYCYTIDINE, FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS
RP   OF ARG-104 AND ASP-133.
RX   PubMed=20614893; DOI=10.1021/bi100839e;
RA   Hazra S., Ort S., Konrad M., Lavie A.;
RT   "Structural and kinetic characterization of human deoxycytidine kinase
RT   variants able to phosphorylate 5-substituted deoxycytidine and
RT   thymidine analogues.";
RL   Biochemistry 49:6784-6790(2010).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) IN COMPLEX WITH ACYCLOVIR AND
RP   UDP.
RX   PubMed=20684612; DOI=10.1021/jm1005379;
RA   Hazra S., Konrad M., Lavie A.;
RT   "The sugar ring of the nucleoside is required for productive substrate
RT   positioning in the active site of human deoxycytidine kinase (dCK):
RT   implications for the development of dCK-activated acyclic guanine
RT   analogues.";
RL   J. Med. Chem. 53:5792-5800(2010).
CC   -!- FUNCTION: Required for the phosphorylation of the
CC       deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and
CC       deoxyadenosine (dA). Has broad substrate specificity, and does not
CC       display selectivity based on the chirality of the substrate. It is
CC       also an essential enzyme for the phosphorylation of numerous
CC       nucleoside analogs widely employed as antiviral and
CC       chemotherapeutic agents. {ECO:0000269|PubMed:18377927,
CC       ECO:0000269|PubMed:20614893}.
CC   -!- CATALYTIC ACTIVITY: NTP + deoxycytidine = NDP + dCMP.
CC       {ECO:0000269|PubMed:12808445, ECO:0000269|PubMed:18377927,
CC       ECO:0000269|PubMed:19159229, ECO:0000269|PubMed:20614893}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.2 uM for deoxycytidine (dC) {ECO:0000269|PubMed:12808445};
CC         KM=15.5 uM for cytarabine (araC) {ECO:0000269|PubMed:12808445};
CC         KM=22 uM for gemcitabine (dC) {ECO:0000269|PubMed:12808445};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:12808445,
CC       ECO:0000269|PubMed:16421443, ECO:0000269|PubMed:19836232,
CC       ECO:0000269|PubMed:20614893, ECO:0000269|PubMed:20684612}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9342341}.
CC   -!- PTM: Phosphorylated and activated in vitro upon phosphorylation at
CC       Ser-74 by CSNK1D/CK1. {ECO:0000269|PubMed:20637175}.
CC   -!- SIMILARITY: Belongs to the DCK/DGK family. {ECO:0000305}.
CC   -!- CAUTION: Was shown to be phosphorylated and activated by
CC       CSNK1D/CK1 in vitro but probably not in vivo.
CC       {ECO:0000305|PubMed:20637175}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M60527; AAA35752.1; -; mRNA.
DR   EMBL; AK313523; BAG36303.1; -; mRNA.
DR   EMBL; CR536527; CAG38764.1; -; mRNA.
DR   EMBL; CR541876; CAG46674.1; -; mRNA.
DR   EMBL; BT019941; AAV38744.1; -; mRNA.
DR   EMBL; BT019942; AAV38745.1; -; mRNA.
DR   EMBL; CH471057; EAX05637.1; -; Genomic_DNA.
DR   EMBL; BC103764; AAI03765.1; -; mRNA.
DR   EMBL; BC114617; AAI14618.1; -; mRNA.
DR   CCDS; CCDS3548.1; -.
DR   PIR; A38585; A38585.
DR   RefSeq; NP_000779.1; NM_000788.2.
DR   UniGene; Hs.709; -.
DR   PDB; 1P5Z; X-ray; 1.60 A; B=1-260.
DR   PDB; 1P60; X-ray; 1.96 A; A/B=1-260.
DR   PDB; 1P61; X-ray; 2.21 A; B=1-260.
DR   PDB; 1P62; X-ray; 1.90 A; B=1-260.
DR   PDB; 2A2Z; X-ray; 3.02 A; A/B/C/D=1-260.
DR   PDB; 2A30; X-ray; 3.02 A; A/B/C/D=1-260.
DR   PDB; 2A7Q; X-ray; 2.55 A; A=1-260.
DR   PDB; 2NO0; X-ray; 1.80 A; A/B=1-260.
DR   PDB; 2NO1; X-ray; 1.91 A; A/B=1-260.
DR   PDB; 2NO6; X-ray; 1.90 A; A/B=1-260.
DR   PDB; 2NO7; X-ray; 1.70 A; A/B=1-260.
DR   PDB; 2NO9; X-ray; 2.15 A; A/B=1-260.
DR   PDB; 2NOA; X-ray; 1.80 A; A/B=1-260.
DR   PDB; 2QRN; X-ray; 3.40 A; A/B/C/D=1-260.
DR   PDB; 2QRO; X-ray; 3.45 A; A/B/C/D=1-260.
DR   PDB; 2ZI3; X-ray; 2.30 A; A/B=1-260.
DR   PDB; 2ZI4; X-ray; 2.10 A; A=1-260.
DR   PDB; 2ZI5; X-ray; 1.77 A; A/B/C/D=1-260.
DR   PDB; 2ZI6; X-ray; 1.77 A; A/B/C/D=1-260.
DR   PDB; 2ZI7; X-ray; 1.97 A; A/B=1-260.
DR   PDB; 2ZI9; X-ray; 2.51 A; A/B=1-260.
DR   PDB; 2ZIA; X-ray; 1.80 A; A/B=1-260.
DR   PDB; 3HP1; X-ray; 2.31 A; A=1-260.
DR   PDB; 3IPX; X-ray; 2.00 A; A=20-260.
DR   PDB; 3IPY; X-ray; 2.54 A; A/B=20-260.
DR   PDB; 3KFX; X-ray; 1.96 A; A/B=1-260.
DR   PDB; 3MJR; X-ray; 2.10 A; A/B/C/D=1-260.
DR   PDB; 3QEJ; X-ray; 2.49 A; A/B=1-260.
DR   PDB; 3QEN; X-ray; 2.00 A; A/B=1-260.
DR   PDB; 3QEO; X-ray; 1.90 A; A/B=1-260.
DR   PDB; 4JLJ; X-ray; 2.00 A; A/B=1-260.
DR   PDB; 4JLK; X-ray; 1.89 A; A/B=1-260.
DR   PDB; 4JLM; X-ray; 2.18 A; A/B=1-260.
DR   PDB; 4JLN; X-ray; 2.15 A; A/B=1-260.
DR   PDB; 4KCG; X-ray; 2.09 A; A/B=1-260.
DR   PDB; 4L5B; X-ray; 1.94 A; A/B=1-260.
DR   PDB; 4Q18; X-ray; 2.00 A; A/B=1-260.
DR   PDB; 4Q19; X-ray; 2.09 A; A/B=1-260.
DR   PDB; 4Q1A; X-ray; 1.90 A; A/B=1-260.
DR   PDB; 4Q1B; X-ray; 2.15 A; A/B=1-260.
DR   PDB; 4Q1C; X-ray; 2.00 A; A/B=1-260.
DR   PDB; 4Q1D; X-ray; 2.00 A; A/B=1-260.
DR   PDB; 4Q1E; X-ray; 1.85 A; A/B=1-260.
DR   PDB; 4Q1F; X-ray; 2.10 A; A/B=1-260.
DR   PDBsum; 1P5Z; -.
DR   PDBsum; 1P60; -.
DR   PDBsum; 1P61; -.
DR   PDBsum; 1P62; -.
DR   PDBsum; 2A2Z; -.
DR   PDBsum; 2A30; -.
DR   PDBsum; 2A7Q; -.
DR   PDBsum; 2NO0; -.
DR   PDBsum; 2NO1; -.
DR   PDBsum; 2NO6; -.
DR   PDBsum; 2NO7; -.
DR   PDBsum; 2NO9; -.
DR   PDBsum; 2NOA; -.
DR   PDBsum; 2QRN; -.
DR   PDBsum; 2QRO; -.
DR   PDBsum; 2ZI3; -.
DR   PDBsum; 2ZI4; -.
DR   PDBsum; 2ZI5; -.
DR   PDBsum; 2ZI6; -.
DR   PDBsum; 2ZI7; -.
DR   PDBsum; 2ZI9; -.
DR   PDBsum; 2ZIA; -.
DR   PDBsum; 3HP1; -.
DR   PDBsum; 3IPX; -.
DR   PDBsum; 3IPY; -.
DR   PDBsum; 3KFX; -.
DR   PDBsum; 3MJR; -.
DR   PDBsum; 3QEJ; -.
DR   PDBsum; 3QEN; -.
DR   PDBsum; 3QEO; -.
DR   PDBsum; 4JLJ; -.
DR   PDBsum; 4JLK; -.
DR   PDBsum; 4JLM; -.
DR   PDBsum; 4JLN; -.
DR   PDBsum; 4KCG; -.
DR   PDBsum; 4L5B; -.
DR   PDBsum; 4Q18; -.
DR   PDBsum; 4Q19; -.
DR   PDBsum; 4Q1A; -.
DR   PDBsum; 4Q1B; -.
DR   PDBsum; 4Q1C; -.
DR   PDBsum; 4Q1D; -.
DR   PDBsum; 4Q1E; -.
DR   PDBsum; 4Q1F; -.
DR   ProteinModelPortal; P27707; -.
DR   SMR; P27707; -.
DR   BioGrid; 108001; 22.
DR   IntAct; P27707; 5.
DR   MINT; MINT-1387532; -.
DR   STRING; 9606.ENSP00000286648; -.
DR   BindingDB; P27707; -.
DR   ChEMBL; CHEMBL2447; -.
DR   DrugBank; DB02594; 2'-Deoxycytidine.
DR   DrugBank; DB00242; Cladribine.
DR   DrugBank; DB00631; Clofarabine.
DR   DrugBank; DB05494; CP-4055.
DR   DrugBank; DB00987; Cytarabine.
DR   DrugBank; DB01262; Decitabine.
DR   DrugBank; DB00879; Emtricitabine.
DR   DrugBank; DB01073; Fludarabine.
DR   DrugBank; DB00441; Gemcitabine.
DR   DrugBank; DB00709; Lamivudine.
DR   DrugBank; DB01280; Nelarabine.
DR   DrugBank; DB00642; Pemetrexed.
DR   DrugBank; DB04961; Troxacitabine.
DR   DrugBank; DB00943; Zalcitabine.
DR   iPTMnet; P27707; -.
DR   PhosphoSitePlus; P27707; -.
DR   BioMuta; DCK; -.
DR   DMDM; 118447; -.
DR   EPD; P27707; -.
DR   MaxQB; P27707; -.
DR   PaxDb; P27707; -.
DR   PeptideAtlas; P27707; -.
DR   PRIDE; P27707; -.
DR   DNASU; 1633; -.
DR   Ensembl; ENST00000286648; ENSP00000286648; ENSG00000156136.
DR   GeneID; 1633; -.
DR   KEGG; hsa:1633; -.
DR   UCSC; uc003hfx.4; human.
DR   CTD; 1633; -.
DR   DisGeNET; 1633; -.
DR   GeneCards; DCK; -.
DR   HGNC; HGNC:2704; DCK.
DR   HPA; HPA059609; -.
DR   HPA; HPA062773; -.
DR   MIM; 125450; gene.
DR   neXtProt; NX_P27707; -.
DR   OpenTargets; ENSG00000156136; -.
DR   PharmGKB; PA137; -.
DR   eggNOG; KOG4235; Eukaryota.
DR   eggNOG; COG1428; LUCA.
DR   GeneTree; ENSGT00510000046588; -.
DR   HOGENOM; HOG000290165; -.
DR   HOVERGEN; HBG006216; -.
DR   InParanoid; P27707; -.
DR   KO; K00893; -.
DR   PhylomeDB; P27707; -.
DR   TreeFam; TF324413; -.
DR   BioCyc; MetaCyc:HS08100-MONOMER; -.
DR   BRENDA; 2.7.1.74; 2681.
DR   Reactome; R-HSA-73614; Pyrimidine salvage reactions.
DR   Reactome; R-HSA-74217; Purine salvage.
DR   SABIO-RK; P27707; -.
DR   ChiTaRS; DCK; human.
DR   EvolutionaryTrace; P27707; -.
DR   GeneWiki; Deoxycytidine_kinase; -.
DR   GenomeRNAi; 1633; -.
DR   PRO; PR:P27707; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000156136; -.
DR   CleanEx; HS_DCK; -.
DR   ExpressionAtlas; P27707; baseline and differential.
DR   Genevisible; P27707; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004137; F:deoxycytidine kinase activity; IDA:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0019206; F:nucleoside kinase activity; EXP:Reactome.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0043101; P:purine-containing compound salvage; TAS:Reactome.
DR   GO; GO:0043097; P:pyrimidine nucleoside salvage; TAS:Reactome.
DR   GO; GO:0006220; P:pyrimidine nucleotide metabolic process; IDA:UniProtKB.
DR   InterPro; IPR002624; DCK/DGK.
DR   InterPro; IPR031314; DNK_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF01712; dNK; 1.
DR   PIRSF; PIRSF000705; DNK; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome;
KW   Direct protein sequencing; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Transferase.
FT   CHAIN         1    260       Deoxycytidine kinase.
FT                                /FTId=PRO_0000175090.
FT   NP_BIND      28     36       ATP.
FT   NP_BIND     188    192       ATP.
FT   NP_BIND     240    242       ATP.
FT   ACT_SITE    127    127       Proton acceptor. {ECO:0000255}.
FT   BINDING      53     53       Substrate.
FT   BINDING      86     86       Substrate.
FT   BINDING      97     97       Substrate.
FT   BINDING     128    128       Substrate.
FT   BINDING     133    133       Substrate.
FT   BINDING     197    197       Substrate.
FT   MOD_RES      11     11       Phosphoserine; by CK1.
FT                                {ECO:0000305|PubMed:20637175}.
FT   MOD_RES      15     15       Phosphoserine; by CK1.
FT                                {ECO:0000305|PubMed:20637175}.
FT   MOD_RES      72     72       Phosphothreonine; by CK1.
FT                                {ECO:0000305|PubMed:20637175}.
FT   MOD_RES      74     74       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:20637175}.
FT   MUTAGEN     100    100       A->V: Strongly increased catalytic
FT                                efficiency towards deoxycytidine; when
FT                                associated with M-104 and A-133.
FT                                {ECO:0000269|PubMed:12808445}.
FT   MUTAGEN     104    104       R->L: Strongly increased catalytic
FT                                efficiency towards deoxythymidine; when
FT                                associated with A-133.
FT                                {ECO:0000269|PubMed:12808445,
FT                                ECO:0000269|PubMed:19159229,
FT                                ECO:0000269|PubMed:20614893}.
FT   MUTAGEN     104    104       R->M: Strongly increased catalytic
FT                                efficiency towards deoxycytidine; when
FT                                associated with V-100 and A-133.
FT                                {ECO:0000269|PubMed:12808445,
FT                                ECO:0000269|PubMed:19159229,
FT                                ECO:0000269|PubMed:20614893}.
FT   MUTAGEN     133    133       D->A: Strongly increased catalytic
FT                                efficiency towards deoxycytidine; when
FT                                associated with V-100 and M-104. Strongly
FT                                increased catalytic efficiency towards
FT                                deoxythymidine; when associated with L-
FT                                104. {ECO:0000269|PubMed:12808445,
FT                                ECO:0000269|PubMed:19159229,
FT                                ECO:0000269|PubMed:20614893}.
FT   CONFLICT    122    122       P -> S (in Ref. 4; AAV38744/AAV38745).
FT                                {ECO:0000305}.
FT   STRAND       22     27       {ECO:0000244|PDB:1P5Z}.
FT   HELIX        34     38       {ECO:0000244|PDB:1P5Z}.
FT   TURN         39     41       {ECO:0000244|PDB:1P5Z}.
FT   HELIX        42     44       {ECO:0000244|PDB:1P5Z}.
FT   STRAND       48     51       {ECO:0000244|PDB:1P5Z}.
FT   HELIX        55     58       {ECO:0000244|PDB:1P5Z}.
FT   STRAND       61     63       {ECO:0000244|PDB:2A2Z}.
FT   HELIX        69     72       {ECO:0000244|PDB:2NO7}.
FT   HELIX        73     77       {ECO:0000244|PDB:2ZI6}.
FT   HELIX        81     87       {ECO:0000244|PDB:1P5Z}.
FT   HELIX        89    112       {ECO:0000244|PDB:1P5Z}.
FT   HELIX       115    118       {ECO:0000244|PDB:1P5Z}.
FT   STRAND      119    121       {ECO:0000244|PDB:1P5Z}.
FT   STRAND      123    128       {ECO:0000244|PDB:1P5Z}.
FT   HELIX       130    135       {ECO:0000244|PDB:1P5Z}.
FT   HELIX       137    143       {ECO:0000244|PDB:1P5Z}.
FT   HELIX       149    170       {ECO:0000244|PDB:1P5Z}.
FT   STRAND      173    179       {ECO:0000244|PDB:1P5Z}.
FT   HELIX       182    192       {ECO:0000244|PDB:1P5Z}.
FT   HELIX       195    197       {ECO:0000244|PDB:1P5Z}.
FT   HELIX       202    216       {ECO:0000244|PDB:1P5Z}.
FT   HELIX       226    230       {ECO:0000244|PDB:1P5Z}.
FT   STRAND      233    237       {ECO:0000244|PDB:1P5Z}.
FT   HELIX       242    258       {ECO:0000244|PDB:1P5Z}.
SQ   SEQUENCE   260 AA;  30519 MW;  626B9D2D6BED8DBC CRC64;
     MATPPKRSCP SFSASSEGTR IKKISIEGNI AAGKSTFVNI LKQLCEDWEV VPEPVARWCN
     VQSTQDEFEE LTMSQKNGGN VLQMMYEKPE RWSFTFQTYA CLSRIRAQLA SLNGKLKDAE
     KPVLFFERSV YSDRYIFASN LYESECMNET EWTIYQDWHD WMNNQFGQSL ELDGIIYLQA
     TPETCLHRIY LRGRNEEQGI PLEYLEKLHY KHESWLLHRT LKTNFDYLQE VPILTLDVNE
     DFKDKYESLV EKVKEFLSTL
//
